ライフサイエンスコーパス: phosphotyrosine

1 varphi is a hydrophobic amino acid and pY is phosphotyrosine).

2 cific for phosphoserine, phosphothreonine or phosphotyrosine.

3 to bind phosphorylated substrates including phosphotyrosine.

4 ractions beyond the classical recognition of phosphotyrosine.

5 signaling interactions beyond recognition of phosphotyrosine.

6 s analyzed using specific antibodies against phosphotyrosine.

7 und peptides containing phosphothreonine and phosphotyrosine.

8 a BV-tag-labeled monoclonal antibody against phosphotyrosine.

9 tual amino acid sequence and position of the phosphotyrosines.

10 "knocked-in" EpoR mutant lacking cytoplasmic phosphotyrosines.

11 ated with the unusual SH2 recognition of two phosphotyrosines.

12 hifts in the spectroscopic identification of phosphotyrosines.

13 Cbl can directly bind cMet at phosphotyrosine 1003 or indirectly via Grb2 to phosphoty

14 osphotyrosine 1003 or indirectly via Grb2 to phosphotyrosine 1356 in the multisubstrate binding domai

15 a potential GADD34 phosphatase, recognizing phosphotyrosine 262.

16 Although Stat5 binds to EPO-R phosphotyrosine 343, the initial Stat5-deficient mice di

17 mortem samples, there was an accumulation of phosphotyrosine 39 alpha-synuclein in brain tissues and

18 This study further indicates that phosphotyrosine 39 alpha-synuclein is a potential diseas

19 tivation led to an age-dependent increase in phosphotyrosine 39 alpha-synuclein.

20 ne 416 (stimulatory site) and down-regulated phosphotyrosine 527 (inhibitory site) in retinal cells,

21 Transgenic osteoclasts showed a lower c-Src phosphotyrosine 527 level, greater c-Src kinase activity

22 PTPL1 dephosphorylates phosphotyrosine 55 of TRIP6 in vitro and inhibits LPA-in

23 shing indicated that SOCS6 binds directly to phosphotyrosines 591 and 919 of Flt3.

24 Localization requires phosphotyrosine, Abl and Src family tyrosine kinases, an

25 However, phosphotyrosine accounts for less than 1% of all phospho

26 Crystallography of the cores of phosphotyrosine-activated dimers of STAT1 (132-713) and

27 re, we investigated the possibility that the phosphotyrosine adaptor protein ShcA regulates nephrin t

28 bstitute tyrosine 104 with chemically stable phosphotyrosine analogue (p-Carboxymethyl-L-phenylalanin

29 alidation of the predicted sites using a pan-phosphotyrosine and a site-specific antibody, which we g

30 an increase in PI3K enzyme activity in anti-phosphotyrosine and anti-IGF-1R immunoprecipitates of RO

31 ntrols both steady-state and poststimulation phosphotyrosine and calcium levels.

32 to the synapse, suppressing accumulation of phosphotyrosine and myosin without affecting F-actin.

33 ing complexes using a bilayered mechanism of phosphotyrosine and proline-rich anchoring motifs.

34 that cis-interactions between the C-terminal phosphotyrosines and SH2 domain within the protein tyros

35 iched in TCR, protein kinase C-theta, ZAP70, phosphotyrosine, and HS1), forming what we term a podo-s

36 blots were performed for MKP-1, phospho-JNK, phosphotyrosine, and protein kinase Cdelta (PKCdelta).

37 binding partner, suggesting that Nck couples phosphotyrosine- and phosphoinositide-dependent signals.

38 gets and represents a key connection linking phosphotyrosine- and phosphoserine/threonine-mediated on

39 Anti-phosphotyrosine antibodies were used to purify tyrosine

40 ng EGFR antibodies and Western blotting with phosphotyrosine antibodies.

41 ith EGFR antibody followed by detection with phosphotyrosine antibody revealed that erlotinib effecti

42 is of mouse oocytes and zygotes with an anti-phosphotyrosine antibody revealed that fertilization sti

43 There were small increases in total phosphotyrosine at the anergic synapse along with signif

44 Phosphotyrosine-based peptidomimetic inhibitors, which m

45 suggest a model in which dynamic changes in phosphotyrosine-based signaling confer plasticity to the

46 Because phosphotyrosine-based signaling in hematopoietic cells i

47 Phosphotyrosine-based signaling plays a vital role in ce

48 Nck links phosphotyrosine-based signaling to Arp2/3-dependent acti

49 , we define a novel mechanism where the CCM2 phosphotyrosine binding (PTB) domain binds the ubiquitin

50 ion of KRIT1 and CCM2 and find that the CCM2 phosphotyrosine binding (PTB) domain displays a preferen

51 cellular experiments now show that the Mint1 phosphotyrosine binding (PTB) domain that binds to APP i

52 Shc comprises an N-terminal phosphotyrosine binding (PTB) domain, a C-terminal Src h

53 rtually every human Src homology 2 (SH2) and phosphotyrosine binding (PTB) domain, as well as microar

54 s of a Pleckstrin Homology (PH) domain and a Phosphotyrosine Binding (PTB) domain.

55 protein containing pleckstrin homology (PH), phosphotyrosine binding (PTB), and leucine zipper motifs

56 tions with PKC-theta occurred independent of phosphotyrosine binding and Fyn.

57 The cell fate determinant Numb is a phosphotyrosine binding domain (PTB)-containing endocyti

58 ses mapped the ERalpha binding domain to the phosphotyrosine binding domain 2 (PTB2).

59 otein containing pleckstrin homology domain, phosphotyrosine binding domain and leucine zipper motif)

60 uncation mutant consisting of the N-terminal phosphotyrosine binding domain blocks PP1-Axin interacti

61 erface with MDM2, only one region within the phosphotyrosine binding domain of NUMB (amino acids 113-

62 AB-6.2 bound to and colocalized with the PDZ/phosphotyrosine binding domain protein LIN-10.

63 eta phosphorylation site also located in the phosphotyrosine binding domain, threonine 206, had no ph

64 g of proteins that contain Src homology 2 or phosphotyrosine binding domains and whether mechanisms i

65 e to investigate the effect of disruption of phosphotyrosine binding of the N-terminal SH2 domain of

66 eport the discovery of malonate bound in the phosphotyrosine binding pocket of the apo-Grb7-SH2 struc

67 analogues were designed on the basis of the phosphotyrosine binding pocket of the Src SH2 domain and

68 The phosphotyrosine binding region, but not the PDZ-binding

69 to design inhibitors blocking its SH2 domain phosphotyrosine binding site that is responsible for bot

70 s between the two SH2 domains distant to the phosphotyrosine binding sites, Syk dissociates from the

71 Hakai acts through its phosphotyrosine-binding (HYB) domain, which bears a dime

72 59249, p.Arg125Trp) in the N-terminal TBC1D1 phosphotyrosine-binding (PTB) domain has shown a replica

73 sent the detailed structural analysis of Shc phosphotyrosine-binding (PTB) domain in complex with the

74 step in this process involves interaction of phosphotyrosine-binding (PTB) domain in the N-terminal h

75 rystal structure at 1.37-A resolution of the phosphotyrosine-binding (PTB) domain of ARH in complex w

76 These characteristics are conserved in the phosphotyrosine-binding (PTB) domain of beta-amyloid pre

77 Here we show that the phosphotyrosine-binding (PTB) domain protein Ced-6, a we

78 mprises a pleckstrin-homology (PH) domain, a phosphotyrosine-binding (PTB) domain, and C-terminal sit

79 ontaining a pleckstrin-homology (PH) domain, phosphotyrosine-binding (PTB) domain, and leucine zipper

80 ontaining a pleckstrin homology (PH) domain, phosphotyrosine-binding (PTB) domain, and leucine zipper

81 Dab2, through its phosphotyrosine-binding (PTB) domain, inhibits platelet

82 ophic factor receptors predominantly via its phosphotyrosine-binding (PTB) domain.

83 e intrinsic EGFR kinase, as well as the ShcD phosphotyrosine-binding (PTB) domain.

84 ing modules such as Src homology 2 (SH2) and phosphotyrosine-binding (PTB) domains.

85 orylated and bind proteins containing SH2 or phosphotyrosine-binding (PTB) domains.

86 ay of interactions that likely includes both phosphotyrosine-binding and SH3-domain-containing protei

87 Tyr(313)-phosphorylated hinge region and its phosphotyrosine-binding C2 domain that controls PKCdelta

88 variants that differ in the length of their phosphotyrosine-binding domain (PTB) and proline-rich re

89 tor-like protein that contains an N-terminal phosphotyrosine-binding domain and a C-terminal Src homo

90 if is predicted to bind directly to the Numb phosphotyrosine-binding domain and is critical for Numb

91 cterize such interaction networks within the phosphotyrosine-binding domain of insulin receptor subst

92 Similarly, the phosphotyrosine-binding domain of IRS-1 mediates a direc

93 This interaction occurred between the phosphotyrosine-binding domain of SH2D5 and an NxxF moti

94 n containing a pleckstrin-homology domain, a phosphotyrosine-binding domain, and a leucine zipper mot

95 ant, inactive IRS-1 protein (deletion of the phosphotyrosine-binding domain, PTB) and does not requir

96 omain linked to a PH domain and a C-terminal phosphotyrosine-binding domain.

97 ein receptor family members by recognizing a phosphotyrosine-binding domain.

98 However, CFTR does not possess a phosphotyrosine-binding domain.

99 proteins containing a Src homology 2 and/or phosphotyrosine-binding domain.

100 Unlike the monomeric nature of the SH2 and phosphotyrosine-binding domains, the architecture of the

101 pter protein that possesses an SH2 and a PTB phosphotyrosine-binding motif.

102 e SH2 domain surface, far from the classical phosphotyrosine-binding pocket.

103 cture of the HYB domain is essential for the phosphotyrosine-binding property of Hakai.

104 Memo thus represents a new class of phosphotyrosine-binding protein.

105 hat, in the nematode Caenorhabditis elegans, phosphotyrosine-binding pseudo-phosphatases are key regu

106 mology 2 (SH2) and kinase domains and to the phosphotyrosine-binding site of the SH2 domain, respecti

107 KCtheta and specifically required a putative phosphotyrosine-binding site within its N-terminal C2 do

108 Through 7 phosphoinositide 3-kinase (PI3K) phosphotyrosine-binding sites, ErbB3 is able to recruit

109 ture/function approach, we now show that the phosphotyrosine-binding, but not the Src homology 2, dom

110 ich involves a transesterification to form a phosphotyrosine bond within the RepD active site, is clo

111 1-associated DNA breaks via hydrolysis of 3'-phosphotyrosine bonds.

112 We report that phosphotyrosine-cholesterol conjugates effectively and s

113 competent position at rates that mirror the phosphotyrosine cleavage kinetics.

114 y 2 (SH2) domain-containing proteins and the phosphotyrosine-containing counterparts play significant

115 n the absence and in the presence of a bound phosphotyrosine-containing peptide.

116 cking methods to identify phosphoserine- and phosphotyrosine-containing peptides as possible substrat

117 ng the nSH2-helical domain contact caused by phosphotyrosine-containing peptides binding to the enzym

118 hat the Vav2 SH2 domain binds selectively to phosphotyrosine-containing peptides corresponding to cor

119 ime-resolved luminescence of Tb(3+)-chelated phosphotyrosine-containing peptides, which facilitated e

120 tic ER microsomes identified 49 high scoring phosphotyrosine-containing peptides.

121 inase inhibitor, K-252a, and purification of phosphotyrosine-containing proteins allowed for definiti

122 ings demonstrate that FAK depletion switches phosphotyrosine-containing proteins from focal adhesions

123 se families, stimulate the ubiquitination of phosphotyrosine-containing proteins, including receptor

124 The SLP-76 phosphotyrosine-containing sequence, pY(173)IDR, does no

125 rexpression in HEK293 cells increases global phosphotyrosine content, promotes anchorage-independent

126 ession levels, probe signal is linked to the phosphotyrosine-correlated activation state of the ERBB2

127 ing and dissociation of effectors containing phosphotyrosine-dependent binding modules such as Src ho

128 , it binds SHP-1 and SHP-2 phosphatases in a phosphotyrosine-dependent manner, facilitating their rec

129 cal importance, how vascular cells integrate phosphotyrosine-dependent signaling to elicit cytoskelet

130 ss of 170amu to Tyr411 to yield the o-cresyl phosphotyrosine derivative.

131 structure and dynamics of complexes of three phosphotyrosine-derived peptides with the Src SH2 domain

132 rowth factor, there are only two established phosphotyrosine-docking sites (Tyr-490 and Tyr-785 on Tr

133 or tyrosine kinases generally act by forming phosphotyrosine-docking sites on their own endodomains t

134 Phosphotyrosine enrichment used immunoprecipitation and

135 we combine this approach with immunoaffinity phosphotyrosine enrichment, enabling the identification

136 This regulation depends upon phosphotyrosine-EphrinB2 signalling repressing c-jun N-t

137 e ShK-170 (ShK-L5), containing an N-terminal phosphotyrosine extension of the Stichodactyla helianthu

138 l-cysteine-l-phenylalanine, or l-cysteine-l-phosphotyrosine formed on crystallographically textured

139 osine (160-fold), sulfotyrosine (3600-fold), phosphotyrosine (>8000-fold), and phosphoserine (>8000-f

140 Phosphotyrosine hydrolysis by protein tyrosine phosphata

141 ures is comparable to the specificity of the phosphotyrosine immonium ion for phosphotyrosine peptide

142 s, the characteristic 16O1- and 18O1-labeled phosphotyrosine immonium ions at m/z 216.043 and 218.047

143 We employed proteomic screening by phosphotyrosine immunoaffinity purification and tandem m

144 vity in cell extracts using traditional anti-phosphotyrosine immunodetection and chemifluorescence.

145 Proteome analysis was based on 2D-DIGE, phosphotyrosine immunoprecipitations followed by 1D SDS-

146 ur finding that v-Src increased the level of phosphotyrosine in cellular proteins in RSV-transformed

147 on in IFNLR1 mimics the mode of binding of a phosphotyrosine in classical SH2 domains.

148 amplified cell lines also contained elevated phosphotyrosine in EGFR, Her2, and Erbb3, but the elevat

149 ephosphorylation cascade directed in part at phosphotyrosine in myosin.

150 Src homology 2 domain binds directly to two phosphotyrosines in HS1.

151 sequences of approximately 100 aa that bind phosphotyrosines in signaling proteins and thereby media

152 tion of PLC-gamma1 by Itk requires a direct, phosphotyrosine-independent interaction between the Src

153 ec kinases and provides evidence of a novel, phosphotyrosine-independent regulatory role for the ubiq

154 Second, we identified a non-canonical, phosphotyrosine-independent STAT3 activation motif withi

155 depends on a tyrosine in DCL1 (Y442) but is phosphotyrosine-independent, a highly unusual feature fo

156 Hence, this interaction is phosphotyrosine-independent, and GRB10 SH2 can bind the

157 O6 is present on peripheral adaptor protein, phosphotyrosine interacting with PH domain and leucine z

158 each in calponin homology 1 (CH1) domain and phosphotyrosine interaction domain (PID) of Shc.

159 Phosphotyrosine Interaction Domain containing 1 (PID1; N

160 ternative methods for membrane anchoring and phosphotyrosine interaction in cytoplasmic kinases, and

161 concomitant decline of Ca(2+) dampens the C2-phosphotyrosine interaction so that PLCgamma2 activation

162 94Asn]) in the gene for the Adaptor Protein, Phosphotyrosine Interaction, PH domain, and leucine zipp

163 1 and APPL2 proteins (APPL (adaptor protein, phosphotyrosine interaction, pleckstrin homology (PH) do

164 e affinities and specificities of SH2 domain-phosphotyrosine interactions have been well characterize

165 ins and thus can serve as competitors of SH2-phosphotyrosine interactions.

166 sual as it was not entirely dependent on SH2-phosphotyrosine interactions.

167 yrosine relaxase enzymes can accommodate two phosphotyrosine intermediates within their divalent meta

168 egion 2600-2605 and incorporated unprotected phosphotyrosine into IkappaB-alpha using a modified gene

169 bosomes capable of incorporating unprotected phosphotyrosine into proteins from a phosphotyrosyl-tRNA

170 show that the elevated EGFR, Her2, and Erbb3 phosphotyrosine is dependent on FGFR2, revealing EGFR fa

171 aling leads to aberrant expression of RON, a phosphotyrosine kinase receptor, and that signaling by R

172 resulting in the activation of the specific phosphotyrosine kinases SRC, LYN, and SYK and the concom

173 methyl-d-aspartic acid receptor subunit NR2B phosphotyrosine labeling.

174 B cell activation was indicated by high phosphotyrosine levels in caps and patches, expression o

175 otion is reinforced by their decreased total phosphotyrosine levels, mirroring a postactivated stage,

176 rise to both increased growth and decreased phosphotyrosine levels; cellular PTP activity can theref

177 ng into a SH2-like domain in the presence of phosphotyrosine ligands.

178 required for the precise positioning of the phosphotyrosine linkage for nucleophilic attack by the 3

179 valently bound to its substrate 5'-end via a phosphotyrosine linkage.

180 by cleaving DNA strands and forming covalent phosphotyrosine linkages.

181 Here, we reconstitute phosphotyrosine-mediated assembly of extended linker for

182 itors (TKIs), which has uncovered widespread phosphotyrosine-mediated regulation of drug transporters

183 provide insight into Eya's participation in phosphotyrosine-mediated signaling networks by demonstra

184 ssibility of integrating the newly developed phosphotyrosine mimetic moiety into inhibitors designed

185 Here we have incorporated a novel phosphotyrosine mimetic, which is an unusual amino acid

186 The interaction is independent of both a phosphotyrosine motif and a proline-rich sequence, the c

187 ich bears a dimeric fold that recognizes the phosphotyrosine motifs of E-cadherin, cortactin, DOK1, a

188 ntains a sterile-alpha motif (SAM) domain, 3 phosphotyrosine motifs, a proline-rich region, and a Src

189 The competitiveness of two phosphotyrosines, namely pY542 and pY580, for cis-intera

190 s in a Ca(2+)-regulated manner to a distinct phosphotyrosine of SLP65.

191 he interaction of the Grb2 SH2 domain with a phosphotyrosine on LAT.

192 rc homology (SH) 2 domain binds two specific phosphotyrosines on cortactin, a known Abl/Arg substrate

193 5 regulatory subunit of PI3K, which binds to phosphotyrosines on EpoR.

194 pHis or 3-pHis; they do not cross-react with phosphotyrosine or the other pHis isomer.

195 with peroxidase-like activity to facilitate phosphotyrosine (p-Tyr) oxidation.

196 The phosphotyrosines (p-Tyr) then recruit a subset of approx

197 vation of Ras and ERK but not for other FGFR phosphotyrosine pathways.

198 order to visualize synaptic accumulation of phosphotyrosine, paxillin, F-actin, and the major motor

199 The series of phosphotyrosine peptide derivatives comprises the natura

200 We evaluated active kinases using phosphotyrosine peptide enrichment and quantitative mass

201 Phosphotyrosine peptide enrichment and quantitative mass

202 n and displaces fluorescein-labeled GpYLPQTV phosphotyrosine peptide from binding to STAT3.

203 method, targeted ECD allows analysis of both phosphotyrosine peptides and lower abundance phosphopept

204 e identification of 3168 unique nonredundant phosphotyrosine peptides in two LC-MS/MS runs from 8 mg

205 spectrometric data set of affinity-purified phosphotyrosine peptides obtained from normal and cancer

206 city of the phosphotyrosine immonium ion for phosphotyrosine peptides, allowing the efficient data co

207 Proteomic analysis revealed several novel phosphotyrosine peptides, including Harvey rat sarcoma o

208 the opposite direction to that of canonical phosphotyrosine peptides, which may contribute to their

209 nd inactivation of Src homology 2-containing phosphotyrosine phosphatase (SHP-2).

210 activity and suggested the involvement of a phosphotyrosine phosphatase 1b (PTP1b) in this process.

211 VEGFR2 by calpain via its substrate protein phosphotyrosine phosphatase 1B (PTP1B), and the relevanc

212 on of suppressor of cytokine signaling-3 and phosphotyrosine phosphatase 1B, two negative regulators

213 3-kinase (PI3K) or SRC homology 2-containing phosphotyrosine phosphatase 2 (SHP2).

214 ich is stimulated by Ephrin A1 (EfnA1) or by phosphotyrosine phosphatase inhibition.

215 g in hematopoietic cells is regulated by the phosphotyrosine phosphatase SHP-1, which is not implied

216 cal probes for second-site screening against phosphotyrosine phosphatases (PTPs) using NMR-based tech

217 phosphotyrosine signaling-tyrosine kinases, phosphotyrosine phosphatases, and Src Homology 2 (SH2) d

218 ing mechanism was ROS-mediated inhibition of phosphotyrosine phosphatases, which antagonize receptor

219 alyzed phosphorylation is counterbalanced by phosphotyrosine phosphatases.

220 Polyomaviruses have shown the importance of phosphotyrosine, PI3K, and p53 in transformation.

221 signaling pathways in HNSCC, we compared the phosphotyrosine profiles of a panel of HNSCC cell lines

222 highlights the application and potential of phosphotyrosine profiling for identifying clinically rel

223 ted under these conditions with quantitative phosphotyrosine profiling identified 193 differentially

224 We integrated a quantitative phosphotyrosine profiling method with 'spike-in' stable

225 ome similarity to that of low-molecular-mass phosphotyrosine protein phosphatase, although Ssu72 has

226 hanced binding to the critical actin-binding phosphotyrosine protein, cortactin.

227 pressed within cells and can covalently trap phosphotyrosine proteins on exposure to light.

228 ylated peptides, corresponding to 844 unique phosphotyrosine proteins.

229 Analysis of the phosphotyrosine proteome in paclitaxel-resistant tumor c

230 Using a phosphotyrosine proteomics approach, we screened the HNS

231 t nature of hydrogen bonding interactions in phosphotyrosine (pTyr) and sulfotyrosine (sTyr) residues

232 these effects, we analyzed the stability of phosphotyrosine (pTyr) sites in ovarian and colon tumors

233 e kinases, 38 tyrosine phosphatases, and 123 phosphotyrosine (pTyr)-binding SH2 proteins, all higher

234 Phosphotyrosine (pTyr)-dependent signaling is critical f

235 ng interactions involving the SH2 domain and phosphotyrosine(pTyr)-based inhibitors.

236 SH2 domains recognize phosphotyrosine (pY) in the context of particular sequen

237 specificity is highly biased toward a single phosphotyrosine (pY) motif among many potential pYXNX Gr

238 to discover a BCR-ABL fusion in H929 cells: phosphotyrosine (pY) peptide IP, p85 regulatory subunit

239 th similar affinities to known Stat3-binding phosphotyrosine (pY) peptide motifs, including those of

240 veal hypothesized novel EPOR/JAK2 targets, a phosphotyrosine (PY) phosphoproteomics approach was appl

241 Succinate- and cyclopropane-derived phosphotyrosine (pY) replacements were incorporated into

242 inhibition increased the exchange rate of a phosphotyrosine (pY) reporter (dSH2) at IACs.

243 H2 ligand, a constrained mimic, in which the phosphotyrosine (pY) residue is preorganized in the boun

244 e binding of Src-homology 2 (SH2) domains to phosphotyrosine (pY) sites is critical for the autoinhib

245 for specific and absolute quantification of phosphotyrosine (pY) under the assistance of a protein t

246 reventing dephosphorylation of substrate Lck phosphotyrosine (pY)-505 versus preventing dephosphoryla

247 VHZ efficiently catalyzes the hydrolysis of phosphotyrosine (pY)-containing peptides but exhibits no

248 otein interaction domain that directs myriad phosphotyrosine (pY)-signaling pathways.

249 ) and carboxyphenylalanine (cF) as mimics of phosphotyrosine (pY).

250 RTK(571-999) in incubations with recombinant phosphotyrosine-recognition sequences expressed as GST-f

251 hrough binding of the Nck1 SH2 domain to the phosphotyrosine residue at position 602 (Y602) of the Ep

252 consisting of an N-capped d-tetrapeptide, a phosphotyrosine residue, and a diester or a diamide grou

253 inds of D-tetrapeptide containing one or two phosphotyrosine residues and with the N-terminal capped

254 We find that phosphotyrosine residues on ErbB1 have half-lives of a f

255 SH2 domain of STAT6 to block recruitment to phosphotyrosine residues on IL-4 or IL-13 receptors and

256 interaction between the STATc SH2 domain and phosphotyrosine residues on Pyk2 that are generated by a

257 d a ShcA mutant (R175Q) that no longer binds phosphotyrosine residues via its PTB domain.

258 dephosphorylation on the critical 1007-1008 phosphotyrosine residues, implying JAK2 inhibition and t

259 of neighboring negatively charged N-terminal phosphotyrosine residues, promoting swelling of caveolae

260 By interacting with specific phosphotyrosine residues, they provide regulatable prote

261 necessary for the formation of invadopodia, phosphotyrosine-rich structures which degrade the extrac

262 ns from 8 mg of HeLa peptides, each with 80% phosphotyrosine selectivity, at a peptide FDR of 0.2%.

263 are transcription factors that dimerize via phosphotyrosine-SH2 domain interactions.

264 , weakening of the inhibitory intramolecular phosphotyrosine-SH2 interaction, and amplification of a

265 ivision, NMY-2 is required for SRC-dependent phosphotyrosine signaling and acts in parallel with WNT-

266 in the modulation of point contact dynamics, phosphotyrosine signaling at filopodial tips, and lamell

267 ne kinases, suggesting an important role for phosphotyrosine signaling in the green algae.

268 e performed a quantitative comparison of the phosphotyrosine signaling network and resulting phenotyp

269 etic nephropathy, has been shown to activate phosphotyrosine signaling pathways in human podocytes.

270 Multiple angiogenic cues modulate phosphotyrosine signaling to promote vasculogenesis and

271 Until recently, phosphotyrosine signaling was thought to be restricted t

272 Yet the three-part toolkit that regulates phosphotyrosine signaling-tyrosine kinases, phosphotyros

273 nding the evolutionary origins of SH2 domain-phosphotyrosine signaling.

274 ll receptor signal transduction by enhancing phosphotyrosine signals and intracellular calcium fluxes

275 h lower levels of early signaling events and phosphotyrosine signals at the pSMAC.

276 The family of Nck adaptors couples phosphotyrosine signals with actin dynamics and therefor

277 Mutation of a phosphotyrosine site of the essential STPK PknB reduces

278 Moreover, hierarchical clustering of phosphotyrosine sites could accurately classify these le

279 SP) and an SH2 domain that binds to multiple phosphotyrosine sites in the adhesion protein nephrin, l

280 ated basal autophosphorylation at five known phosphotyrosine sites.

281 e purified phosphorylated protein bound to a phosphotyrosine specific antibody and permitted NF-kappa

282 mong the first to recognize the potential of phosphotyrosine-specific antibodies, Parsons and colleag

283 , substrates, and pathways through which the phosphotyrosine-specific ubiquitin ligases regulate dive

284 escence colocalization of Muc1/TLR5 and Muc1/phosphotyrosine staining patterns in mouse airway epithe

285 principally recognizes the phosphate of its phosphotyrosine substrate and further stabilizes the tyr

286 zation of HYB(DeltaC) can be induced using a phosphotyrosine substrate peptide.

287 A peptide bound in the active site mimics a phosphotyrosine substrate, affords insight into substrat

288 ability, ShK-192, contains a nonhydrolyzable phosphotyrosine surrogate, a methionine isostere, and a

289 Src family kinases, decreased the amount of phosphotyrosine syntrophin and decreased the level of ac

290 lar calcium and accumulated higher levels of phosphotyrosine than control T cells.

291 N-Fmoc and O-Et protected phosphoserine and phosphotyrosine to prepare molecularly imprinted monolit

292 Despite harboring two potential phosphotyrosine (Tyr(P)) recognition domains, SH2D5 bind

293 rts have established that GIV is involved in phosphotyrosine (Tyr(P))-based signaling in response to

294 differing only in their N-terminal residue, phosphotyrosine vs lysine, coassemble as stacks of antip

295 n the human genome that show specificity for phosphotyrosine, we identified six PTPs by quantitative

296 itored by either yeast-growth curves or anti-phosphotyrosine Western blots.

297 yl amino propionic acid (pCAP), an analog of phosphotyrosine, which can be incorporated into peptides

298 coumaryl amino propionic acid, an analog of phosphotyrosine, which can be incorporated into peptides

299 rosine phosphatase that targets two critical phosphotyrosines within GIV and antagonizes phospho-GIV-

300 a marked increase in binding affinity of the phosphotyrosine-Y699 with the mutant histidine.